[HTML][HTML] Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences

Y Ye, Z Huang, M Zhang, J Li, Y Zhang… - Biomedicine & …, 2023 - Elsevier
Abstract The phosphoinositide 3-kinase (PI3K) signaling pathway is well-known for its
important role in cancer growth, proliferation and migration. The activation of PI3K pathway …

[HTML][HTML] mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

Y Hu, F Chen, S Sun, L Xv, X Wang, M Wang… - Frontiers in …, 2024 - frontiersin.org
This study aimed to explore the efficacy and potential mechanisms of rechallenge therapy
with microtubule-targeting agents (MTAs) in patients with HER2-low metastatic breast …

[HTML][HTML] β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models

I Korovina, M Elser, O Borodins, M Seifert… - Biomedicine & …, 2024 - Elsevier
Abstract Phosphoinositide 3-kinase (PI3K)-α represents a key intracellular signal transducer
involved in the regulation of key cell functions such as cell survival and proliferation …

Constructed risk prognosis model associated with disulfidptosis lncRNAs in HCC

X Jia, Y Wang, Y Yang, Y Fu, Y Liu - International Journal of Molecular …, 2023 - mdpi.com
Disulfidptosis is a novel cell death mode in which the accumulation of disulfide bonds in
tumor cells leads to cell disintegration and death. Long-stranded noncoding RNAs …

Molecular interactions and binding dynamics of Alpelisib with serum albumins: insights from multi-spectroscopic techniques and molecular docking

A Jalan, NS Moyon - Journal of Biomolecular Structure and …, 2024 - Taylor & Francis
Alpelisib (ALP) is a potent anti-cancer drug showing promising activity against advanced
breast cancers. Hence, profound understanding of its binding dynamics within the …

Clinical value of identifying genes that inhibit hepatocellular carcinomas

U Testa, E Pelosi, G Castelli - Expert Review of Molecular …, 2022 - Taylor & Francis
Introduction Primary liver cancer is a major health problem being the sixth most frequent
cancer in the world and the fourth most frequent cause of cancer-related death in the world …

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells

M Piazzi, A Bavelloni, V Cenni, S Salucci… - Molecules, 2022 - mdpi.com
Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric cancer arising
from skeletal muscle myogenic progenitors. Recent studies have shown an important role for …

Cyclin-dependent kinase 4/6 inhibitors: A potential breakthrough therapy for malignancies of gastrointestinal tract

F Zeng, Y Zhou, T Khowtanapanich, C Saengboonmee - in vivo, 2022 - iv.iiarjournals.org
Cancer is the leading cause of death worldwide for which effective treatments remain
limited. This article aimed to critically review and discuss the potential of targeting cell cycle …

Synthetic vulnerabilities in the KRAS pathway

M Roman, E Hwang, EA Sweet-Cordero - Cancers, 2022 - mdpi.com
Simple Summary Despite recent dramatic progress, developing drugs that target oncogenic
KRAS or its key effectors remains a major challenge for cancer research. Improving our …

[HTML][HTML] CRISPR/Cas9 genetic screens in hepatocellular carcinoma gene discovery

CH Chiu - Current Research in Biotechnology, 2023 - Elsevier
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated protein 9 (Cas9) system is a powerful gene editing tool originated from …